Division of Merck & Co. Inc.
Latest From MSD KK
The Turkish government’s drive to establish domestic manufacturing for vaccines is showing tentative signs of getting off the ground. New partnerships are forming between Turkish and international partners. However, lack of local know-how is hampering progress.
A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.
Keytruda has been approved in Japan for lung cancer, including first-line use, in a batch of new regulatory clearances that also include the country's first prescription drug for irritable bowel syndrome with constipation.
Hot on the heels of Keytruda's US approval for first-line use in lung cancer, and just ahead of the drug’s first local launch, rival PD-1 player Ono has launched a patent infringement suit in Japan against Merck, adding to similar actions brought elsewhere by its global Opdivo partner BMS.
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Tony Alvarez, Pres.
- Contact Info
Phone: 03 6272 0088
13th No. 12 Kitanomaru Sq.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.